The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
Launched by NEXGEN DERMATOLOGICS, INC. · Jun 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of 3% kanuka oil compared to 1% hydrocortisone cream in treating atopic dermatitis, a skin condition that affects many people and often causes intense itching. The goal is to see if this natural oil, which is available over-the-counter, can provide relief for those suffering from this condition.
To participate in the trial, you must be over 12 years old and have been diagnosed with atopic dermatitis for at least two years. You should also have a certain level of itchiness, measured by a simple scale. However, if you have used certain treatments like steroid creams in the past month, or if you are pregnant or nursing, you won't be eligible to join. If you do participate, you can expect to use either the kanuka oil or the hydrocortisone cream for the duration of the study and help researchers learn more about effective treatments for atopic dermatitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age greater than 12 years, diagnosis of atopic dermatitis for longer than 2 years, investigator's static global assessment score of either 2 or 3, and initial worst itch numerical rating scale (WI-NRS) for itch greater than 4.
- Exclusion Criteria:
- • the use of topical or systemic corticosteroids within 28 days of entering the study, the use of any other non-emollient therapy within 28 days of entering the study,nursing, and pregnancy
About Nexgen Dermatologics, Inc.
Nexgen Dermatologics, Inc. is a pioneering clinical trial sponsor dedicated to advancing dermatological research and improving patient outcomes through innovative therapeutic solutions. With a focus on developing novel treatments for a range of skin conditions, the company leverages cutting-edge science and technology to drive clinical development. Committed to rigorous standards of safety and efficacy, Nexgen collaborates with leading researchers and healthcare professionals to ensure that its trials meet the highest ethical and regulatory benchmarks. Through its robust pipeline of clinical studies, Nexgen Dermatologics aims to transform the landscape of dermatology and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boynton Beach, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported